tolterodine + terazosin

The combination of tolterodine and terazosin is used to treat lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). This combination therapy has been studied for its efficacy in improving urinary symptoms, particularly in men with BPH and in patients with ureteral stent-related discomfort. Terazosin is an alpha-1 blocker that works by relaxing the muscles in the bladder and prostate, which helps improve urinary flow and reduce symptoms of BPH. It's typically administered at a dose of 2 mg once or twice daily. Tolterodine is an anticholinergic agent that treats symptoms of overactive bladder by relaxing bladder muscles. It's usually given at a dose of 2 mg once or twice daily in combination therapy. Clinical studies have shown that the combination of terazosin and tolterodine provides significant improvements in International Prostate Symptom Scores (IPSS), particularly for irritative symptoms like urgency, frequency, and nocturia. The combination therapy has demonstrated better efficacy than either drug alone in reducing LUTS associated with BPH. In studies examining ureteral stent-related symptoms, the combination of terazosin plus tolterodine significantly improved irritative symptoms, quality of life, flank pain, voiding pain, and decreased the need for analgesics compared to placebo. The most common adverse effect associated with this combination is dry mouth, which is typically related to the anticholinergic properties of tolterodine. The incidence of adverse effects is generally higher with the combination therapy compared to terazosin alone. This combination therapy represents a good approach for achieving rapid, sustained, and safe improvements in LUTS associated with BPH, particularly for patients who continue to experience symptoms after initial treatment with alpha blockers alone.

Other names

combination therapy (tolterodine and terazosin)